BACKGROUND: Studies have also shown that differences in the kind of the antipsychotics influenced disruption of the sensorimotor gating system, including prepulse inhibition (PPI), acoustic startle reflex (ASR), and habituation (HAB). We investigated the influence on startle response in chronic schizophrenia in 20 patients with schizophrenia taking risperidone, 21 patients with schizophrenia taking olanzapine, and 20 patients with schizophrenia taking aripiprazole. METHOD: The patients who participated in this study were on maintenance therapy with only one antipsychotic drug for 4 months. We performed the test for the association between all PPI measures (ASR, HAB, and PPI at prepulse sound pressure intensities of 82, 86, and 90 dB) and each the risperidene, olanzapine, and aripiprazole groups, with analysis of covariance (ANCOVA; using age, duration of illness, and daily dose of the antipsychotic as covariates). Also, when significant difference was detected in ANCOVA, the differences of PPI measures between every pairs of two drug groups were tested as a post hoc analysis with the use of t test and Bonferroni's correction of multiple tests. RESULT: We found that PPI90 showed significant differences with ANCOVA among patients with schizophrenia taking each of the antipsychotics. When we performed a post hoc analysis for PPI90, the value was higher in the aripiprazole group than in the olanzapine group and higher in the risperidone group than in the olanzapine group. CONCLUSION: Aripiprazole and risperidone may improve PPI90. ASR, HAB, PPI82, and PPI86 were no different among the Japanese schizophrenic patient groups with different antipsychotics.
BACKGROUND: Studies have also shown that differences in the kind of the antipsychotics influenced disruption of the sensorimotor gating system, including prepulse inhibition (PPI), acoustic startle reflex (ASR), and habituation (HAB). We investigated the influence on startle response in chronic schizophrenia in 20 patients with schizophrenia taking risperidone, 21 patients with schizophrenia taking olanzapine, and 20 patients with schizophrenia taking aripiprazole. METHOD: The patients who participated in this study were on maintenance therapy with only one antipsychotic drug for 4 months. We performed the test for the association between all PPI measures (ASR, HAB, and PPI at prepulse sound pressure intensities of 82, 86, and 90 dB) and each the risperidene, olanzapine, and aripiprazole groups, with analysis of covariance (ANCOVA; using age, duration of illness, and daily dose of the antipsychotic as covariates). Also, when significant difference was detected in ANCOVA, the differences of PPI measures between every pairs of two drug groups were tested as a post hoc analysis with the use of t test and Bonferroni's correction of multiple tests. RESULT: We found that PPI90 showed significant differences with ANCOVA among patients with schizophrenia taking each of the antipsychotics. When we performed a post hoc analysis for PPI90, the value was higher in the aripiprazole group than in the olanzapine group and higher in the risperidone group than in the olanzapine group. CONCLUSION:Aripiprazole and risperidone may improve PPI90. ASR, HAB, PPI82, and PPI86 were no different among the Japanese schizophrenicpatient groups with different antipsychotics.
Authors: N R Swerdlow; M A Geyer; P L Hartman; J Sprock; P P Auerbach; K Cadenhead; W Perry; D L Braff Journal: Psychopharmacology (Berl) Date: 1999-09 Impact factor: 4.530
Authors: Jonathan K Wynn; Michael F Green; Joyce Sprock; Gregory A Light; Clifford Widmark; Christopher Reist; Stephen Erhart; Stephen R Marder; Jim Mintz; David L Braff Journal: Schizophr Res Date: 2007-07-26 Impact factor: 4.939
Authors: Nancy A Shanahan; Kerri A Holick Pierz; Virginia L Masten; Christian Waeber; Mark Ansorge; Jay A Gingrich; Mark A Geyer; Rene Hen; Stephanie C Dulawa Journal: Biol Psychiatry Date: 2008-11-14 Impact factor: 13.382
Authors: R E Nordquist; C Risterucci; J L Moreau; M von Kienlin; B Künnecke; M Maco; C Freichel; C Riemer; W Spooren Journal: Neuropharmacology Date: 2007-10-26 Impact factor: 5.250
Authors: Morgane Thomsen; Gitta Wörtwein; Anders Fink-Jensen; David P D Woldbye; Jürgen Wess; S Barak Caine Journal: Psychopharmacology (Berl) Date: 2007-02-20 Impact factor: 4.415
Authors: Antonio Ortega-Alvaro; Auxiliadora Aracil-Fernández; María S García-Gutiérrez; Francisco Navarrete; Jorge Manzanares Journal: Neuropsychopharmacology Date: 2011-03-23 Impact factor: 7.853